Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice
Circulation - United States
doi 10.1161/circulationaha.113.001278
Full Text
Open PDFAbstract
Available in full text
Date
May 28, 2013
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)